Term
|
Definition
| selective estrogen receptor modulators |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
fulvestrant
ER (promotes its destruction) |
|
|
Term
|
Definition
aromatase is necessary to produce estrogen
are used in menopause because the ovaries of premenopausal women can produce enough aromatase to override the inhibition. |
|
|
Term
|
Definition
Anastrozole
Aromatase inhibitors |
|
|
Term
|
Definition
exemestane
Aromatase inhibitors |
|
|
Term
|
Definition
letrozole
Aromatase inhibitors |
|
|
Term
|
Definition
Imatinib mesylate
TKs
gastrointestinal stromal tumor, leukemia, dermatofibrosarcoma protuberans, myelodysplastic/myeloproliferative disorders, and systemic mastocytosis. |
|
|
Term
|
Definition
Dasatinib
TKs
some patients with CML or ALL |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
Trastuzumab
HER-2
breast cancer as well as some types of gastric or gastroesophageal junction adenocarcinoma.
Trastuzumab may have other effects as well, such as inducing the immune system |
|
|
Term
|
Definition
Pertuzumab
HER-2
metastatic breast HER-2+
monoclonal binds region allows HER-2 to interact with other receptors, eg EGFR
immune system to attack HER-2-expressing cells. |
|
|
Term
|
Definition
Lapatinib
TKs
certain types of advanced or metastatic breast cancer. |
|
|
Term
|
Definition
Gefitinib
kinase activity of EGFR
advanced non-small cell lung cancer. |
|
|
Term
|
Definition
Erlotinib
kinase activity of EGFR
metastatic non-small cell lung cancer and pancreatic cancer that cannot be removed by surgery or has metastasized |
|
|
Term
|
Definition
Cetuximab
monoclonal antibody
squamous cell carcinoma of the head and neck or colorectal cancer. The drug binds to the external portion of EGFR |
|
|
Term
|
Definition
Panitumumab
EGFR
metastatic colon cancer. |
|
|
Term
|
Definition
Temsirolimus
mTOR
advanced renal cell carcinoma. |
|
|
Term
|
Definition
Everolimus
immunophilin FK binding protein-12, forming a complex that binds to and inhibits the mTOR kinase
advanced kidney cancer . Subependymal giant cell astrocytoma, advanced breast cancer, or patients with pancreatic neuroendocrine tumors |
|
|
Term
|
Definition
Vandetanib
TKs (EGFR, VEGFRs, and RET)
metastatic medullary thyroid cancer who are ineligible for surgery. |
|
|
Term
|
Definition
Vemurafenib
BRAF V600E
inoperable or metastatic melanoma. |
|
|
Term
|
Definition
Crizotinib
EML4-ALK
metastatic non-small cell lung cancer |
|
|
Term
|
Definition
Vorinostat
HDACs
cutaneous T-cell lymphoma (CTCL) that has persisted, progressed, or recurred during or after treatment with other medicines. |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
Panretin
retinoic acid receptors and retinoid X receptors
cutaneous lesions in patients with AIDS-related Kaposi sarcoma. |
|
|
Term
|
Definition
Tretinoin
retinoid
induction of remission in certain patients with acute promyelocytic leukemia. |
|
|
Term
|
Definition
Bortezomib
proteasome
multiple myeloma, mantle cell lymphoma. inhibitors. |
|
|
Term
|
Definition
Carfilzomib
proteasome
multiple myeloma inhibitor. |
|
|
Term
|
Definition
Pralatrexate peripheral
anitfolate
T-cell lymphoma.
Other antifolates, such as methotrexate, are not considered targeted therapies because they interfere all dividing cells. However, pralatrexate appears to selectively accumulate in cells that express RFC-1 |
|
|
Term
|
Definition
Bevacizumab
VEGF
glioblastoma. also approved non-small cell lung cancer, metastatic colorectal cancer, and metastatic kidney cancer |
|
|
Term
|
Definition
Ziv-aflibercept
portions of two different VEGF receptors
recombinant fusion protein
metastatic colorectal cancer |
|
|
Term
|
Definition
Sorafenib
tyrosine kinases, VEGF signaling pathway
advanced renal cell carcinoma and some cases of hepatocellular carcinoma. |
|
|
Term
|
Definition
Sunitinib
tyrosine kinase VEGF signaling
metastatic renal cell carcinoma, gastrointestinal stromal tumor or pancreatic neuroendocrine tumors that cannot be removed by surgery, are locally advanced, or have metastasized. |
|
|
Term
|
Definition
Pazopanib
TKs (VEGF receptors, c-KIT, PDGF)
advanced renal cell carcinoma and advanced soft tissue sarcoma |
|
|
Term
|
Definition
Regorafenib
TKs ( VEGF receptors, the angiopoietin-1 receptor (TIE2), PDGFR, RET, c-KIT, and RAF)
metastatic colorectal cancer |
|
|
Term
|
Definition
Cabozantinib
TKs (VEGF receptors, RET, MET, TRKB, and TIE2)
metastatic medullary thyroid cancer |
|
|
Term
|
Definition
Rituximab
mAb CD20 monoclonal antibody
B-cell non-Hodgkin lymphoma and, when combined with other drugs, to treat chronic lymphocytic leukemia (CLL). triggers an immune response that results in their destruction. Rituximab may also induce apoptosis. |
|
|
Term
|
Definition
Alemtuzumab B-cell
mAb CD52, a protein found on the surface of normal and malignant B and T cells and many other cells of the immune system |
|
|
Term
|
Definition
Ofatumumab
CD20 cell surface antigen
CLL that does not respond to treatment with fludarabine and alemtuzumab. B-cell |
|
|
Term
|
Definition
Ipilimumab
mAb cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)
unresectable or metastatic melanoma.
By inhibiting CTLA-4, ipilimumab stimulates the immune system to attack melanoma cells. |
|
|
Term
|
Definition
Tositumomab and 131I-tositumomab
mixture mAbs CD20 molecule, some hav I131
B-cell non-Hodgkin lymphoma. |
|
|
Term
|
Definition
Ibritumomab tiuxetan
CD20 mAb bind radioisotopes such as indium-111 or yttrium-90.
B-cell non-Hodgkin lymphoma. |
|
|
Term
|
Definition
Denileukin diftitox
IL-2
CTCL
protein sequences fused to diphtheria toxin. |
|
|
Term
|
Definition
Brentuximab vedotin
CD30 monoclonal antibody linked
systemic anaplastic large cell lymphoma and Hodgkin lymphoma that has not responded to prior therapy. Linked to a drug called monomethyl auristatin E (MMAE), which induces cell cycle arrest and apoptosis. |
|
|
